# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-24-074966
Filing Date
2024-06-26
Accepted
2024-06-26 07:25:08
Documents
6
Period of Report
2024-08-12

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | tm2417053-2_def14a.htm | DEF 14A | 818377
2 | GRAPHIC | lg_outlooktherapeutics-4clr.jpg | GRAPHIC | 18748
3 | GRAPHIC | bc_companytsr-4c.jpg | GRAPHIC | 52940
4 | GRAPHIC | bc_netincome-4c.jpg | GRAPHIC | 50588
5 | GRAPHIC | px_24outlookproxy1pg01-bw.jpg | GRAPHIC | 301630
6 | GRAPHIC | px_24outlookproxy1pg02-bw.jpg | GRAPHIC | 268795
| Complete submission text file | 0001104659-24-074966.txt |  | 1718917

Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: DEF 14A | Act: 34 | File No.: 001-37759 | Film No.: 241070616
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)